| Dr Brandon William Segrest, DO | |
|
700 E Ogden Ave Ste 202, Westmont, IL 60559-1296 | |
| (630) 528-3215 | |
| (630) 528-3219 |
| Full Name | Dr Brandon William Segrest |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 6 Years |
| Location | 700 E Ogden Ave Ste 202, Westmont, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063901189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 036156993 (Illinois) | Primary |
| 207R00000X | Internal Medicine | 1063901189 (Michigan) | Secondary |
| 208M00000X | Hospitalist | 036156993 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presence Home Care-kankakee | Bourbonnais, IL | Home health agency |
| Riverside Medical Center | Kankakee, IL | Hospital |
| Miller Health Care Center | Kankakee, IL | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates Of Integrated Medicine Ltd | 3779876636 | 11 |
News Archive
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Insulin uses two distinct mechanisms to control glucose and the metabolism of blood fats (lipids) in the liver, a new Joslin Diabetes Center-led study has discovered.
Researchers at The Cancer Institute at NYU Langone Medical Center is leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.
Mid-level pharmaceutical brands invest an average of $71 million in marketing between Phase III trials and the first year on the market, according to a new report from Cutting Edge Information.
› Verified 6 days ago
| Entity Name | Associates Of Integrated Medicine Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427407345 PECOS PAC ID: 3779876636 Enrollment ID: O20160729001339 |
News Archive
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Insulin uses two distinct mechanisms to control glucose and the metabolism of blood fats (lipids) in the liver, a new Joslin Diabetes Center-led study has discovered.
Researchers at The Cancer Institute at NYU Langone Medical Center is leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.
Mid-level pharmaceutical brands invest an average of $71 million in marketing between Phase III trials and the first year on the market, according to a new report from Cutting Edge Information.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brandon William Segrest, DO 700 E Ogden Ave Ste 202, Westmont, IL 60559-1296 Ph: (630) 528-3215 | Dr Brandon William Segrest, DO 700 E Ogden Ave Ste 202, Westmont, IL 60559-1296 Ph: (630) 528-3215 |
News Archive
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Insulin uses two distinct mechanisms to control glucose and the metabolism of blood fats (lipids) in the liver, a new Joslin Diabetes Center-led study has discovered.
Researchers at The Cancer Institute at NYU Langone Medical Center is leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.
Mid-level pharmaceutical brands invest an average of $71 million in marketing between Phase III trials and the first year on the market, according to a new report from Cutting Edge Information.
› Verified 6 days ago
Laisvyde Smajkic, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 801 N Cass Ave, Ste 150, Westmont, IL 60559 Phone: 630-268-0200 | |
Dr. Vasantha Samala, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 E Ogden Ave, Suite 202, Westmont, IL 60559 Phone: 630-789-9785 Fax: 630-789-9798 | |
Andrew Yu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 303 W Ogden Ave Ste D12, Westmont, IL 60559 Phone: 630-871-6699 | |
Erum Arain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 E Ogden Ave Ste 202, Westmont, IL 60559 Phone: 630-789-9785 | |
Dr. Arnon E Rubin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 E Ogden Ave, Ste 202, Westmont, IL 60559 Phone: 630-789-9785 Fax: 630-789-9798 | |
Melwin Joseph, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 E Ogden Ave Ste 202, Westmont, IL 60559 Phone: 630-528-3215 Fax: 630-528-3219 |